Document is current
Any future updates will be listed below
-
Authors
Moulin, David https://orcid.org/0000-0001-6619-5769
Sellam, Jérémie
Berenbaum, Francis https://orcid.org/0000-0001-8252-7815
Guicheux, Jérôme
Boutet, Marie-Astrid https://orcid.org/0000-0002-1519-6902
- License Information
-
More Information
Article History
Accepted: 31 January 2025
First Online: 13 March 2025
Competing interests
: F.B. received an institutional grant from TRB Chemedica and Pfizer and consulting fees from AstraZeneca, Boehringer Ingelheim, Bone Therapeutics, Cellprothera, Galapagos, Gilead, Grunenthal, GSK, Lilly, MerckSerono, MSD, Nordic Bioscience, Novartis, Pfizer, Roche, Sandoz, Sanofi, Servier, UCB, Peptinov, 4 P Pharma and 4Moving Biotech. J.S. reports personal fees from MSD, Pfizer, AbbVie, Fresenius Kabi, BMS, Lilly, Novartis, Galapagos, AstraZeneca, UCB, Grunenthal and Janssen and research grants from Pfizer and Schwa Medico. J.G. received consulting fees from BMS, Graftys, PKmed, HTL biotechnology, Cellprothera, GSK, Peptinov and CEVA.
